The oral protease inhibitor nirmatrelvir is of key importance for prevention of severe
coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied …

The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …

Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …

Shortly after the onset of the COVID-19 pandemic, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has acquired numerous variations in its intracellular proteins to …

The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …

Variants of SARS-CoV-2 have become a major public health concern due to increased
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …

The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …

SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (M pro) is an
attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical …

Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …